{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T12:13:03Z","timestamp":1773231183003,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,12]],"date-time":"2021-09-12T00:00:00Z","timestamp":1631404800000},"content-version":"am","delay-in-days":346,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002241","name":"Japan Science and Technology Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002241","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.bbrc.2020.08.012","type":"journal-article","created":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T07:33:19Z","timestamp":1597649599000},"page":"636-642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Rictor promotes tumor progression of rapamycin-insensitive triple-negative breast cancer cells"],"prefix":"10.1016","volume":"531","author":[{"given":"Risayo","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamiko","family":"Miyata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5719-9431","authenticated-orcid":false,"given":"Chitose","family":"Oneyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2020.08.012_bib1","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbrc.2020.08.012_bib2","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2020.08.012_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/modpathol.2009.145","article-title":"Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer","volume":"23","author":"Thike","year":"2010","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.bbrc.2020.08.012_bib4","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.21873\/anticanres.13722","article-title":"Triple-negative breast cancer: the progress of targeted therapies and future tendencies","volume":"39","author":"Damaskos","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.bbrc.2020.08.012_bib5","article-title":"Neoadjuvant treatment for triple negative breast cancer: recent progresses and challenges","volume":"12","author":"Lee","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bbrc.2020.08.012_bib6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10549-018-4697-y","article-title":"Targeting the PI3K\/AKT\/mTOR pathway in triple-negative breast cancer: a review","volume":"169","author":"Costa","year":"2018","journal-title":"Breast Canc. Res. Treat."},{"key":"10.1016\/j.bbrc.2020.08.012_bib7","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/annonc\/mdz133","article-title":"Targeting the PI3-kinase pathway in triple-negative breast cancer","volume":"30","author":"Pascual","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbrc.2020.08.012_bib8","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2020.08.012_bib9","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","article-title":"mTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bbrc.2020.08.012_bib10","doi-asserted-by":"crossref","first-page":"48206","DOI":"10.18632\/oncotarget.10195","article-title":"Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers","volume":"7","author":"Hatem","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2020.08.012_bib11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/onc.2012.572","article-title":"Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer","volume":"33","author":"Montero","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2020.08.012_bib12","first-page":"1713","article-title":"Regulation of mTORC1 and its impact on gene expression at a glance","volume":"126","author":"Laplante","year":"2013","journal-title":"J.\u00a0Cell Sci."},{"key":"10.1016\/j.bbrc.2020.08.012_bib13","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.cub.2004.06.054","article-title":"Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton","volume":"14","author":"Sarbassov","year":"2004","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bbrc.2020.08.012_bib14","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2020.08.012_bib15","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/emboj.2008.120","article-title":"The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C","volume":"27","author":"Facchinetti","year":"2008","journal-title":"EMBO J."},{"key":"10.1016\/j.bbrc.2020.08.012_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ddstr.2009.12.001","article-title":"mTOR mediated anti-cancer drug discovery","volume":"6","author":"Liu","year":"2009","journal-title":"Drug Discov. Today Ther. Strat."},{"key":"10.1016\/j.bbrc.2020.08.012_bib17","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1172\/JCI64099","article-title":"Rapalogs and mTOR inhibitors as anti-aging therapeutics","volume":"123","author":"Lamming","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.bbrc.2020.08.012_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2443.2007.01145.x","article-title":"Functional dissection of transformation by c-Src and v-Src","volume":"13","author":"Oneyama","year":"2008","journal-title":"Gene Cell."},{"key":"10.1016\/j.bbrc.2020.08.012_bib19","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1038\/onc.2011.63","article-title":"MicroRNA-mediated downregulation of mTOR\/FGFR3 controls tumor growth induced by Src-related oncogenic pathways","volume":"30","author":"Oneyama","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2020.08.012_bib20","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/onc.2011.367","article-title":"MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression","volume":"31","author":"Oneyama","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2020.08.012_bib21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/onc.2015.110","article-title":"Fer tyrosine kinase oligomer mediates and amplifies Src-induced tumor progression","volume":"35","author":"Oneyama","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2020.08.012_bib22","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1111\/j.1349-7006.2012.02359.x","article-title":"Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells","volume":"103","author":"Yunokawa","year":"2012","journal-title":"Canc. Sci."},{"key":"10.1016\/j.bbrc.2020.08.012_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080300","article-title":"MiR-424\/503-mediated Rictor upregulation promotes tumor progression","volume":"8","author":"Oneyama","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2020.08.012_bib24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/CCO.0000000000000014","article-title":"New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer","volume":"25","author":"Vicier","year":"2013","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.bbrc.2020.08.012_bib25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jbior.2016.12.001","article-title":"Discrete signaling mechanisms of mTORC1 and mTORC2: connected yet apart in cellular and molecular aspects","volume":"64","author":"Jhanwar-Uniyal","year":"2017","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.bbrc.2020.08.012_bib26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.gde.2008.01.004","article-title":"Acquired resistance to tyrosine kinase inhibitors during cancer therapy","volume":"18","author":"Engelman","year":"2008","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.bbrc.2020.08.012_bib27","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1158\/0008-5472.CAN-07-5869","article-title":"Rictor and integrin-linked kinase interact and regulate Akt phosphorylation and cancer cell survival","volume":"68","author":"McDonald","year":"2008","journal-title":"Canc. Res."},{"key":"10.1016\/j.bbrc.2020.08.012_bib28","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/onc.2012.30","article-title":"Role of the integrin-linked kinase (ILK)\/Rictor complex in TGFbeta-1-induced epithelial-mesenchymal transition (EMT)","volume":"32","author":"Serrano","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2020.08.012_bib29","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/carcin\/bgy086","article-title":"Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex","volume":"39","author":"Gkountakos","year":"2018","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.bbrc.2020.08.012_bib30","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119015","article-title":"mLST8 promotes mTOR-mediated tumor progression","volume":"10","author":"Kakumoto","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.bbrc.2020.08.012_bib31","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1158\/0008-5472.CAN-17-2388","article-title":"Selective mTORC2 inhibitor therapeutically blocks breast cancer cell growth and survival","volume":"78","author":"Werfel","year":"2018","journal-title":"Canc. Res."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20315576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20315576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:56:04Z","timestamp":1757764564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X20315576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0006291X20315576"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.08.012","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rictor promotes tumor progression of rapamycin-insensitive triple-negative breast cancer cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}